Terug
47
98
Dagbereik
€ 6,52
€ 6,88
52-Weeksbereik
€ 3,73
€ 10,32
Volume
1.828.145
50D / 200D Gem.
€ 7,85
/
€ 7,50
Vorige Slotkoers
€ 6,52
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 6,2 | 0,4 |
| P/B | 7,2 | 2,9 |
| ROE % | 621,9 | 3,8 |
| Net Margin % | 9,3 | 3,9 |
| Rev Growth 5Y % | 9,7 | 10,0 |
| D/E | 6,9 | 0,2 |
Belangrijkste Punten
Revenue grew 9,73% annually over 5 years — modest growth
ROE of 621,89% indicates high profitability
Debt/Equity of 6,91 — high leverage
Generating 114,79M in free cash flow
P/E of 6,23 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10,46%
Groei
Revenue Growth (5Y)
9,73%
Revenue (1Y)20,19%
Earnings (1Y)N/A
FCF Growth (3Y)163,32%
Kwaliteit
Return on Equity
621,89%
ROIC12,94%
Net Margin9,25%
Op. Margin10,91%
Veiligheid
Debt / Equity
6,91
Current Ratio1,32
Interest Coverage1,89
Waardering
P/E Ratio
6,23
P/B Ratio7,21
EV/EBITDA9,62
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 20,19% | Revenue Growth (3Y) | 13,31% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 9,73% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2,43B | Net Income (TTM) | 225,03M |
| ROE | 621,89% | ROA | 11,18% |
| Gross Margin | 33,09% | Operating Margin | 10,91% |
| Net Margin | 9,25% | Free Cash Flow (TTM) | 114,79M |
| ROIC | 12,94% | FCF Growth (3Y) | 163,32% |
| Safety | |||
| Debt / Equity | 6,91 | Current Ratio | 1,32 |
| Interest Coverage | 1,89 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 6,23 | P/B Ratio | 7,21 |
| P/S Ratio | 0,58 | PEG Ratio | 0,00 |
| EV/EBITDA | 9,62 | Dividend Yield | 0,00% |
| Market Cap | 1,40B | Enterprise Value | 2,55B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,43B | 2,02B | 1,90B | 1,79B | 1,68B |
| Net Income | 225,03M | -10,93M | -134,52M | -662,03M | -117,04M |
| EPS (Diluted) | 1,05 | -0,06 | -0,71 | -3,57 | -0,63 |
| Gross Profit | 805,15M | 635,54M | 595,43M | 553,23M | 542,40M |
| Operating Income | 265,38M | 139,79M | 8,07M | -642,28M | -36,11M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,01B | 1,66B | 1,61B | 1,71B | 2,33B |
| Total Liabilities | 1,82B | 1,79B | 1,74B | 1,72B | 1,70B |
| Shareholders' Equity | 194,46M | -122,09M | -127,44M | -4,18M | 637,95M |
| Total Debt | 1,34B | 1,50B | 1,50B | 1,36B | 1,30B |
| Cash & Equivalents | 193,26M | 84,29M | 43,94M | 19,22M | 30,49M |
| Current Assets | 560,23M | 392,67M | 314,89M | 269,75M | 279,22M |
| Current Liabilities | 424,46M | 402,17M | 354,76M | 326,50M | 344,83M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#204 of 613
#3 of 655
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026